Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
October 04, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s...
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
September 22, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a...
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
September 13, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
August 11, 2022 07:30 ET
|
Abeona Therapeutics Inc.
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient...
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
July 20, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022...
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
June 06, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is...
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 19, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been...
Abeona Therapeutics Reports First Quarter 2022 Financial Results
May 13, 2022 07:30 ET
|
Abeona Therapeutics Inc.
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022 NEW...
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates
May 04, 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Ohio, May 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced the presentation of new...
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 29, 2022 09:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 29, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that preclinical data on...